TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ).
Fusen Pharmaceutical Co., Ltd. announced the approval of its ‘Enzalutamide Soft Capsule’ for marketing in China, targeting non-metastatic and metastatic castration-resistant prostate cancer. This product, developed by its subsidiary Jiaheng Pharmaceutical Technology, aligns with international standards and offers a favorable risk-benefit ratio for patients, enhancing the company’s therapeutic offerings and potentially strengthening its market position in prostate cancer treatment.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and marketing of medical products. The company is involved in producing treatments for various diseases, with a particular emphasis on prostate cancer medications.
Average Trading Volume: 2,167,191
Technical Sentiment Signal: Hold
Current Market Cap: HK$514.7M
Find detailed analytics on 1652 stock on TipRanks’ Stock Analysis page.